Anti-EPCAM CAR-T cell therapy (Sinobioway)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-EPCAM CAR-T cell therapy (Sinobioway)
Drug Alias NameChimeric antigen T-cell therapies - Sinobioway Cell TherapyCAR T-cell therapy-Sinobioway Cell TherapyCAR-T EPCAM therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-EpCAMImmunologic cytotoxicityT lymphocyte replacements
TargetsEpithelial cell adhesion molecule
Therapy Area/IndicationsLiver NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Sinobioway Bioengineering Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Sinobioway Bioengineering Group Co Ltd
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A